The interferon in TLR signaling: More than just antiviral

Trends in Immunology

Volumn 24, Issue 10, 2003, Pages 534-539

  Hertzog, Paul J ^a   O'Neill, Luke A ^b   Hamilton, John A ^c  

^a MONASH UNIVERSITY   (Australia)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; TOLL LIKE RECEPTOR;

BACTERIUM; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC MANIPULATION; GENETIC PROCEDURES; IMMUNE RESPONSE; INFLAMMATION; METABOLIC ACTIVATION; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL PROCESSING;

EID: 0141670818     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.08.006     Document Type: Article

References (62)

1. Janeway C.A. Jr, Medzhitov R. Annu. Rev. Immunol. 20:2002;197-216.
2. Poltorak A., et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:1998;2085-2088.
3. Hoshino K., et al. Cutting edge: toll-like receptor4(TLR4) - deficient mice are hyporesponsive to lipopolysacharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:1999;3749-3752.
4. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell. Signal. 13:2001;85-94.
5. Akira S., et al. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:2001;675-680.
6. Isaacs A., Lindenmann J. Virus interference. 1 The interferon. Proc. R. Soc. B. 147:1957;258-273.
7. Muller M., et al. Functional role of type I and type II interferons in antiviral defence. Science. 264:1994;1918-1921.
8. Hwang S.Y., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons α and β and alters macrophage responses. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11284-11288.
9. Alcami A., Koszinowski U.H. Viral mechanisms of immune evasion. Trends Microbiol. 8:2000;410-418.
10. Gutterman J.U., et al. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. U. S. A. 91:1994;1198-1205.
11. Roberts R.M., et al. The evolution of type I interferons. J. Interferon Cytokine Res. 18:1998;805-816.
12. Taniguchi T., Takaoka A. The interferon α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 14:2002;111-116.
13. Bach E.A., et al. The IFN gamma receptor: a paradigm for cytokine receptor signalling. Annu. Rev. Immunol. 15:1997;563-591.
14. Stark G.R., et al. How cells respond to interferons. Annu. Rev. Biochem. 67:1998;227-264.
15. Dunn G.P., et al. Cancer immunoediting: from immunosurveillance to tumour escape. Nat. Immunol. 3:2002;991-998.
16. Hertzog P.J., et al. Role of interferons in the regulation of cell proliferation, differentiation and development. Mol. Reprod. Dev. 39:1994;226-232.
17. Marie I., et al. Differential viral induction of distinct interferon-alpha genes by positive feedback through IRF7. EMBO J. 17:1998;6660-6669.
18. Toshchakov V., et al. TLR4, but not TLR2 mediates IFNβ-induced STAT1α/β-dependent gene expression in macrophages. Nat. Immunol. 3:2002;392-398.
19. Vogel S.N., Fertsch D. Endogenous interferon production by endotoxin-responsive macrophages provides an autostimulatory differentiation signal. Infect. Immun. 45:1984;417-423.
20. Hamilton J.A., et al. Endogenous IFNαβ suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-α J. Immunol. 156:1996;2553-2557.
21. Vairo G., et al. Biochemical events accompanying macrophage activation and the inhibition of colony stimulating factor-1 induced macrophage proliferation by tumour necrosis factor-α, interferon-γ and lipopolysaccharide. J. Cell. Physiol. 151:1992;630-641.
22. Vadivaloo P.K., et al. Role of type I interferons during macrophage activation by lipopolysaccharide. Cytokine. 12:2000;1639-1646.
23. Vadivaloo P.K., et al. Type I interferons mediate the lipopolysaccharide induction of macrophage cyclinD2. J. Interferon Cytokine Res. 20:2000;355-359.
24. Kawai T., et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167:2001;5887-5894.
25. Doyle S.E., et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 17:2002;251-263.
26. Hoshino K., et al. Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14:2002;1225-1231.
27. Bellardelli F., et al. The neglected role of type I interferons in the T-cell response: implications for its clinical use. Immunol. Today. 17:1996;369-372.
28. Tough D.F., et al. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 272:1996;1947-1950.
29. Akbar A.N., et al. IFN-α and IFN-β: a link between immune memory and chronic inflammation. Immunol. Today. 7:2000;337-342.
30. Karaghiosoff M., et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 4:2003;471-477.
31. Sato M., et al. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441:1998;106-110.
32. Fitzgerald K.A., et al. IKK epsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:2003;491-496.
33. Sharma S., et al. Triggering the interferon antiviral response through an IKK-related pathway. Science. 300:2003;1148-1151.
34. Servant M.J., et al. Multiple signalling pathways leading to the activation of interferon regulatory factor 3. Biochem. Pharmacol. 64:2002;985-992.
35. Malcolm K.C., Worthen G.S. Lipopolysaccharide stimulates p38 dependent induction of antiviral genes in neutrophils independently of paracrine factors. J. Biol. Chem. 278:2003;15693-15701.
36. O'Neill L.A.J. Toll-like receptor signal transduction and the tailoring of innate immunity: a role for Mal? Trends Immunol. 23:2002;296-300.
37. Janssens S., Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signalling. Trends Biochem. Sci. 27:2002;474-482.
38. Fitzgerald K.A., et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 413:2001;78-83.
39. Horng T., et al. TIRAP: an adapter molecule in the Toll signalling pathway. Nat. Immunol. 2:2001;835-841.
40. Shinobu N., et al. Involvement of TIRAP/MAL in signalling for the activation of interferonregulatory factor 3 by lipopolysaccharide. FEBS Lett. 517:2002;251-256.
41. Yamomoto M., et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 420:2002;324-329.
42. Horng T., et al. The adapter molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 420:2002;329-333.
43. Yamamoto M., et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signalling. J. Immunol. 169:2002;6668-6672.
44. Oshiumi H., et al. TICAM an adapter molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. 4:2003;161-167.
45. O'Neill L.A.J., et al. The Toll-IL1 receptor adapter family grows to five members. Trends Immunol. 24:2003;286-289.
46. Maniatis T., et al. Structure and function of the interferon-beta enhanceosome. Cold Spring Harb. Symp. Quant. Biol. 63:1998;609-620.
47. Munsie N., et al. The IFN-beta enhancer: a paradigm for understanding activation and repression of inducible gene expression. Cold Spring Harb. Symp. Quant. Biol. 64:1999;149-159.
48. Reich N.C. Nuclear/cytoplasmic localisation of IRFs in response to viral infection or interferon stimulation. J. Interferon Cytokine Res. 22:2002;103-110.
49. Takayanagi H., et al. RANKL maintains bone homeostasis through c-fos dependent induction of interferon beta. Nature. 416:2002;744-749.
50. Kinjo I., et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 17:2002;583-591.
51. Nakagawa R., et al. SOCS-1 participates in negative regulation of LPS responses. Immunity. 17:2002;677-687.
52. Stoiber D., et al. Lipopolysaccharide induces in macrophages the synthesis of the suppressor or cytokine signalling 3 and suppresses signal transduction in response to the activating factor IFN-γ J. Immunol. 163:1999;2640-2647.
53. Alexander W.A., et al. SOCS1 is a critical inhibitor of interferonγ signalling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:1999;597-608.
54. Kurt-Jones E.A., et al. Pattern recognition receptors TLR4 and Cd14 mediate response to respiratory syncytial virus. Nat. Immunol. 1:2000;398-401.
55. Rassa J.C., et al. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc. Natl. Acad. Sci. U. S. A. 99:2002;2281-2286.
56. Bieback K., et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol. 76:2002;8729-8736.
57. Compton T., et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and toll-like receptor 2. J. Virol. 77:2003;4588-4596.
58. Applequist S.E., et al. Variable expression of toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 14:2002;1065-1074.
59. Muzio M., et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164:2000;5998-6004.
60. Akira S., et al. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85:2003;85-95.
61. Hoebe K., et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature. 424:2003;743-748.
62. Yamamoto M., et al. Role of adapter TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science. 301:2003;640-643.